5 EASY FACTS ABOUT ABBV-744 COMBINATION THERAPY WITH CHEMOTHERAPY DESCRIBED

In Section C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will acquire treatment until finally disease progression or perhaps the contributors are unable to tolerate the study drugs.For all flow cytometry experiments, 10,000 cells for every replicate ended up analy